Celldex Therapeutics (NASDAQ: CLDX) presented additional phase 2 clinical trial data for barzolvolimab in chronic spontaneous urticaria and cold urticaria/symptomatic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE